Whole-breast irradiation after lumpectomy may protect women from recurrence long term

October 21, 2003

SALT LAKE CITY, UTAH---A Fox Chase Cancer Center study of more than 2,700 women with breast cancer who received whole-breast irradiation following lumpectomy identifies a clear benefit that may not be gained with partial breast irradiation. Gary Freedman, M.D., a radiation oncologist at Fox Chase Cancer Center in Philadelphia, Pa., presented the study today at the 45th annual scientific meeting of the American Society of Therapeutic Radiology and Oncology on October 21st in Salt Lake City, Utah. After lumpectomy, the rationale for treating the whole breast with radiation has been the risk of having microscopic tumor cells in other parts of the breast. A majority of cancer recurrences in the breast after lumpectomy with whole-breast irradiation have been reported to occur within the same area of the breast as the initial primary tumor.

There also has been recent interest in treating with focal radiation only the part of the breast containing the primary tumor. This raises the question of how much the standard whole-breast radiation is reducing the risk of recurrence in other parts of the breast. Freedman and his colleagues looked at the overall risk of recurrence after breast-conserving surgery and whole-breast radiation. They also subdivided these into recurrences near the original primary tumor and elsewhere in the treated breast.

By 15 years after treatment, the risk of true local recurrences was 9%. The risk of recurrence in other parts of the breast within 10 years was very low, as had been suggested by prior studies, but by 15 years it was nearly equal to the risk of recurrence in the original breast quadrant.

"While this may seem to support a favorable outcome for replacing whole-breast irradiation with partial-breast irradiation, our study shows a dramatic shift in the location of recurrence between 10 and 15 years after treatment," said Gary M. Freedman, M.D., lead author of the study.

The researchers compared the risk of recurrence elsewhere in the treated breast to the risk of cancer developing in the unaffected, untreated other breast. They found that for most patients, 7 percent of women had recurrences in other parts of the treated breast compared with 14 percent of women whose cancer recurred in the unaffected, untreated breast 15 years after treatment.

"The rate of recurrence in initially unaffected parts of the breast receiving whole-breast irradiation was half that of the other breast," said Freedman. "This suggests that whole-breast irradiation may have a protective effect."

The study found that the lowest risk of recurrence in other parts of the breast, and in the unaffected, unirradiated breast, was associated with the use of tamoxifen in addition to radiation.

Dr. Freedman concluded, "Very long-term follow-up, at least 10 to 15 years, will be needed for any proposed study of partial breast irradiation to show that the risk of recurrence is not significantly different from recurrence after whole-breast irradiation." Other study authors include Alexandra L. Hanlon, Ph.D., and Penny R. Anderson, M.D., of Fox Chase Cancer Center's radiation oncology department.
-end-
Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic, clinical, population and translational research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu or call 1-888-FOX CHASE.

Fox Chase Cancer Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.